港股昭衍新药（06127）今日盘中大涨5.20%，引发市场广泛关注。该公司最新发布的财报显示，2025年前三季度业绩实现扭亏为盈，这一消息似乎成为推动股价上涨的主要因素。
根据公司公告，昭衍新药2025年前三季度实现归属于上市公司股东的净利润8070.61万元人民币，而去年同期为亏损7030.71万元，基本每股收益0.11元。尽管第三季度单季业绩出现下滑，但整体前三季度的业绩改善仍然给投资者带来信心。
值得注意的是，公司董事会还提议取消监事会，将其职能由董事会审计委员会行使。这一公司治理结构的调整也可能影响了投资者的看法。分析人士认为，虽然公司面临市场竞争加剧、订单价格下滑等挑战，但整体业绩的显著改善仍然是支撑股价上涨的关键因素。投资者似乎对昭衍新药的长期发展前景保持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.